Health - Resources and discussion for everything health-related

2321 readers

277 users here now

Health: physical and mental, individual and public.

Discussions, issues, resources, news, everything.

See the pinned post for a long list of other communities dedicated to health or specific diagnoses. The list is continuously updated.

Nothing here shall be taken as medical or any other kind of professional advice.

Commercial advertising is considered spam and not allowed. If you're not sure, contact mods to ask beforehand.

Linked videos without original description context by OP to initiate healthy, constructive discussions will be removed.

Regular rules of lemmy.world apply. Be civil.

founded 1 year ago

MODERATORS

submitted 1 week ago by MicroWave@lemmy.world to c/health@lemmy.world

4 comments fedilink hide all child comments

Summary

Novo Nordisk provided updates on its next-generation obesity and diabetes drug, CagriSema, a potential successor to Ozempic and Wegovy.

CagriSema combines semaglutide with an amylin and calcitonin receptor agonist, promising enhanced weight loss and blood sugar regulation.

Early trials showed 15.6% weight loss over 32 weeks, and executives are optimistic larger trials could show up to 25% weight loss.

Results from late-stage trials are expected by mid-2025.

you are viewing a single comment's thread
view the rest of the comments

[–] sunzu2@thebrainbin.org 1 points 1 week ago

Ohh yes daddy, give me that good shit